Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors

被引：0
|
作者：
Schram, Alison [1 ]
Spreafico, Anna [2 ]
Oliva, Marc [2 ]
Brana, Irene [3 ]
Garralda, Elena [3 ]
Lakhani, Nehal [4 ]
Von Hoff, Daniel [5 ]
Borazanci, Erkut [5 ]
Pandya, Naimish [6 ]
Hoffman, Kimberly [6 ]
Hallett, Robin [6 ]
Giblin, Patricia [6 ]
Anido, Judit [6 ]
Kelly, Adrianne [6 ]
Wasserman, Robert [6 ]
Seoane, Joan [3 ]
Siu, Lillian [2 ]
Hyman, David M. [1 ]
Tabernero, Josep [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] START Midwest, Grand Rapids, MI USA
[5] Honor Hlth, Scottsdale, AZ USA
[6] Northern Biol, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT014
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
    Catherine Delbaldo
    Eric Raymond
    Karina Vera
    Luz Hammershaimb
    Karen Kaucic
    Stéphanie Lozahic
    Michel Marty
    Sandrine Faivre
    Investigational New Drugs, 2008, 26 : 35 - 43
  • [22] Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
    Delbaldo, Catherine
    Raymond, Eric
    Vera, Karina
    Hammershaimb, Luz
    Kaucic, Karen
    Lozahic, Stephanie
    Marty, Michel
    Faivre, Sandrine
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 35 - 43
  • [23] Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
    Colin D. Weekes
    Lee S. Rosen
    Anna Capasso
    Kit Man Wong
    Weilan Ye
    Maria Anderson
    Bruce McCall
    Jill Fredrickson
    Eric Wakshull
    Steve Eppler
    Quyen Shon-Nguyen
    Rupal Desai
    Mahrukh Huseni
    Priti S. Hegde
    Tony Pourmohamad
    Ina Rhee
    Alberto Bessudo
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 339 - 351
  • [24] Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
    Weekes, Colin D.
    Rosen, Lee S.
    Capasso, Anna
    Wong, Kit Man
    Ye, Weilan
    Anderson, Maria
    McCall, Bruce
    Fredrickson, Jill
    Wakshull, Eric
    Eppler, Steve
    Quyen Shon-Nguyen
    Desai, Rupal
    Huseni, Mahrukh
    Hegde, Priti S.
    Pourmohamad, Tony
    Rhee, Ina
    Bessudo, Alberto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 339 - 351
  • [25] Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
    Fujisaka, Yasuhito
    Kurata, Takayasu
    Tanaka, Kaoru
    Kudo, Toshihiro
    Okamoto, Kunio
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Okamoto, Isamu
    Namiki, Masayuki
    Kitamura, Chifumi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 380 - 388
  • [26] Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
    Yasuhito Fujisaka
    Takayasu Kurata
    Kaoru Tanaka
    Toshihiro Kudo
    Kunio Okamoto
    Junji Tsurutani
    Hiroyasu Kaneda
    Isamu Okamoto
    Masayuki Namiki
    Chifumi Kitamura
    Kazuhiko Nakagawa
    Investigational New Drugs, 2015, 33 : 380 - 388
  • [27] Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Takahashi, T.
    Fukutomi, A.
    Miyazaki, M.
    Satoh, T.
    Okamoto, I.
    Nakagawa, K.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFr) monoclonal antibody emd 72000 in patients with EGFr expressing solid tumors
    Schleucher, N
    Tewes, M
    Dirsch, O
    Schmid, KW
    Rosen, O
    Kovar, S
    Seeber, S
    Harstrick, A
    Vanhoefer, U
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S53
  • [29] Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors
    Boku, N.
    Yamazaki, K.
    Fukutomi, A.
    Takahashi, T.
    Yamamoto, N.
    Miyazaki, M.
    Satoh, T.
    Okamoto, I.
    Nakagawa, K.
    Fukuoka, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 134 - 134
  • [30] A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
    Di Giacomo, A. M.
    Schenker, M.
    Medioni, J.
    Mandziuk, S.
    Majem, M.
    Gravis, G.
    Cornfeld, M.
    Ranganathan, S.
    Lou, S.
    Csoszi, T.
    ESMO OPEN, 2024, 9 (03)
12345